HRD Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting hrd clinical trials across 6 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Guangzhou, Guangdong, China, Bordeaux, France, Bournemouth, Dorset, United Kingdom. Updated daily from ClinicalTrials.gov.


HRD Trials at a Glance

6 actively recruiting trials for hrd are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Guangzhou, Bordeaux, and Bournemouth. Lead sponsors running hrd studies include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Duke Street Bio Ltd, and Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd.

Browse hrd trials by phase

Treatments under study

About HRD Clinical Trials

Looking for clinical trials for HRD? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HRD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HRD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd180 enrolled15 locationsNCT06458712
Recruiting
Phase 1Phase 2

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Advanced Solid TumorsSCLCHRD Cancer
National Cancer Institute (NCI)120 enrolled1 locationNCT04826341
Recruiting
Phase 1

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

Breast CancerOvarian CancerMetastatic Solid Tumor+2 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd110 enrolled2 locationsNCT07156253
Recruiting
Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200 enrolled1 locationNCT06255392
Recruiting
Phase 2

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Breast NeoplasmTriple Negative Breast Cancer(TNBC)HRD
Institute of Cancer Research, United Kingdom119 enrolled6 locationsNCT03740893
Recruiting

Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University470 enrolled1 locationNCT06622798